DrugPatentWatch Database Preview
Bayer Healthcare Company Profile
What is the competitive landscape for BAYER HEALTHCARE, and when can generic versions of BAYER HEALTHCARE drugs launch?
There are four US patents protecting BAYER HEALTHCARE drugs.
There are one hundred and sixty-three patent family members on BAYER HEALTHCARE drugs in fifty-three countries and six supplementary protection certificates in three countries.
Summary for Bayer Healthcare
| International Patents: | 163 |
| US Patents: | 4 |
| Tradenames: | 22 |
| Ingredients: | 12 |
| NDAs: | 28 |
| Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | RID MOUSSE | piperonyl butoxide; pyrethrins | AEROSOL;TOPICAL | 021043-001 | Mar 7, 2000 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare Llc | CLARITIN | loratadine | CAPSULE;ORAL | 021952-001 | Jun 16, 2008 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare Llc | ZEGERID OTC | omeprazole; sodium bicarbonate | FOR SUSPENSION;ORAL | 022283-001 | Jun 17, 2013 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Bayer Healthcare Llc | MIRALAX | polyethylene glycol 3350 | FOR SOLUTION;ORAL | 022015-001 | Oct 6, 2006 | OTC | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Bayer Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Llc | ZEGERID OTC | omeprazole; sodium bicarbonate | CAPSULE;ORAL | 022281-001 | Dec 1, 2009 | 7,399,772 | ➤ Sign Up |
| Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | 4,863,931*PED | ➤ Sign Up |
| Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | 4,659,716*PED | ➤ Sign Up |
| Bayer Healthcare Llc | CLARITIN | loratadine | TABLET;ORAL | 019658-002 | Nov 27, 2002 | 4,659,716*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for BAYER HEALTHCARE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 20 mg/1100 mg | ➤ Subscribe | 2010-04-20 |
Non-Orange Book US Patents for Bayer Healthcare
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,514,520 | Stabilized antihistamine syrup | ➤ Sign Up |
| 8,129,386 | Fused azole-pyrimidine derivatives | ➤ Sign Up |
| 6,939,550 | Stabilized antihistamine syrup | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Bayer Healthcare Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 5326092 | ➤ Sign Up |
| New Zealand | 508037 | ➤ Sign Up |
| Mexico | 336057 | ➤ Sign Up |
| South Africa | 200904691 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB11/013 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| C/GB11/015 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| C/GB08/005 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| C/GB01/012 | United Kingdom | ➤ Sign Up | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
